Quarterly ResultJul 23, 2026, 03:21 PM
Utah Medical Products Q2 Sales Down 14.3%, EPS $0.844
AI Summary
Utah Medical Products reported a significant decline in financial performance for Q2 and H1 2026. Net sales for Q2 decreased by 14.3% to $8.5 million, and diluted EPS fell by 10.1% to $0.844. The first half of 2026 saw net sales drop by 12.3% to $17.3 million and diluted EPS by 10.6% to $1.661. The company attributed the declines primarily to the loss of its two largest customers and revised its full-year 2026 sales projection to a 10-13% decrease.
Key Highlights
- Q2 2026 Net Sales decreased 14.3% to $8,529,000.
- Q2 2026 Diluted EPS decreased 10.1% to $0.844.
- H1 2026 Net Sales decreased 12.3% to $17,252,000.
- H1 2026 Diluted EPS decreased 10.6% to $1.661.
- Full-year 2026 sales projected to decline 10-13% compared to 2025.
- Loss of two largest customers resulted in $1,923,000 lower sales in H1 2026.
- Cash and investments increased to $87,528,000 by June 30, 2026.
- H1 2026 litigation expenses were $341,000 higher than H1 2025.
Price Impact
More from UTMD